Asia Partnership Conference of Regenerative Medicine


The APACRM, Asia Partnership Conference of Regenerative Medicine, is aimed at harmonizing and optimizing regulations among Asian countries and regions. It is essential to develop an ideal environment that embraces common understandings of the scientific nature of regenerative medicine such as cell and gene therapy, and their applications for conducting clinical trials and getting approvals in these countries and regions. FIRM genuinely look forward to the prospect of facilitating this multi-national discussion vital for enhancing the well-being of patients in the region.

FIRM has organized the APACRM, an annual conference, since 2018, and taken a role of as the secretariat of APACRM and has closely collaborated with industrial groups such as the China Medicinal Biotech Association (CMBA) in China, Association of Biotechnology Led Enterprises (ABLE) in India, Council for Advanced Regenerative Medicine (CARM) and Strategic Center for Regenerative Medicine (SCRM) in Korea, Singapore Association of Pharmaceuticals Industries (SAPI) in Singapore, and Biotechnology and Pharmaceutical Industries Promotion Office (BPIPO) in Taiwan.

The activities of FIRM in APACRM has been supported not only by the Ministry of Health, Labour and Welfare (MHLW) and the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan, but also by other Asian health authorities, including the Central Drugs Standard Control Organization (CDSCO) in India, Ministry of Food and Drug Safety (MFDS) in Korea, Health Sciences Authority (HSA) in Singapore, and Center for Drug Evaluation (CDE) in Taiwan.


To expedite the launch
of regenerative
medicine and cell
gene therapy for
people in Asia


To promote harmonization and optimization of the regulations on Regenerative Medicine products among Asian countries and territories

To maximize the opportunities in Asian markets, and ensure the creation of a market that is comparable to those in North America and Europe.